Arcapta

Arcapta is a brand name of indacaterol, approved by the FDA in the following formulation(s):

ARCAPTA NEOHALER (indacaterol maleate - powder; inhalation)

• 
  Manufacturer: NOVARTIS
  
  Approval date: July 1, 2011
  
  Strength(s): EQ 75MCG BASE ^[RLD]

Has a generic version of Arcapta been approved?

No. There is currently no therapeutically equivalent version of Arcapta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Arcapta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Beta2-adrenoceptor agonists
  Patent 6,878,721
  Issued: April 12, 2005
  Inventor(s): Cuenoud; Bernard & Bruce; Ian & Fairhurst; Robin Alec & Beattie; David
  Assignee(s): Novartis AG
  Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
  
  Patent expiration dates:
  
  
  • October 10, 2020
    
    ✓ 
    Patent use: THE LONG TERM, ONCE-DAILY MAINTENANCE BROCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 1, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Arcapta Consumer Information (Drugs.com)
• Arcapta Neohaler Consumer Information (Wolters Kluwer)
• Arcapta Neohaler inhalation Consumer Information (Cerner Multum)
• Arcapta Neohaler Advanced Consumer Information (Micromedex)
• Indacaterol Consumer Information (Wolters Kluwer)
• Indacaterol inhalation Consumer Information (Cerner Multum)
• Indacaterol Inhalation Advanced Consumer Information (Micromedex)